Linked Life Data

2510042

Source:http://linkedlifedata.com/resource/pubmed/id/2510042

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
1989-12-18
pubmed:abstractText
Amyloid peptide precursor (APP) gene expression increases in the brains of patients with Alzheimer's disease (AD). Regulation of expression at the transcriptional and posttranscriptional levels contributes significantly to these increases. Polypeptide hormones stimulate the promoter of the APP gene resulting in increased levels of heterogeneous nuclear RNAs (hnRNA). Through splicing, these hnRNAs are processed into 3 or more mature APP RNAs. The amounts of each of these similar but nonidentical APP RNAs may yield ratios of APP proteins which are required for neuronal survival, pathogenesis of neurons and/or produce phenocopies of learning and memory mutants of Drosophila.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0197-4580
pubmed:author
pubmed:issnType
Print
pubmed:volume
10
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
471-3; discussion 477-8
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed:articleTitle
Increasing amyloid peptide precursor production and its impact on Alzheimer's disease.
pubmed:affiliation
Medical Research Division, Lederle Laboratories, American Cyanamid Company, Pearl River, NY 10965.
pubmed:publicationType
Journal Article